XML 23 R12.htm IDEA: XBRL DOCUMENT

Long-Term Investments

9 Months Ended

Sep. 30, 2021

6. LONG-TERM INVESTMENTS

(1)	The ownership percentages of each investee are listed as follows:

	Ownership percentage
	September 30,			December 31,			Accounting
Name of related party	2021			2020			treatments
Braingenesis Biotechnology Co., Ltd.		0.17	%		0.17	%	Cost Method
Genepharm Biotech Corporation		0.70	%		0.70	%	Cost Method
BioHopeKing Corporation		5.90	%		5.90	%	Cost Method
BioFirst Corporation		15.99	%		15.99	%	Equity Method
Rgene Corporation		31.62	%		31.62	%	Equity Method

(2)	The extent the investee relies on the company for its business are summarized as follows:

Name of related party		The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.		No specific business relationship
Genepharm Biotech Corporation		No specific business relationship
BioHopeKing Corporation		Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation		Loaned from the investee and provides research and development support service
Rgene Corporation		Collaborating with the Company to develop and commercialize drugs

(3)	Long-term investment mainly consists of the following:

	September 30, 2021		December 31, 2020
	(Unaudited)
Non-marketable Cost Method Investments, net
Braingenesis Biotechnology Co., Ltd.	$	7,919	$	7,853
Genepharm Biotech Corporation		24,177		23,974
BioHopeKing Corporation		898,068		890,564
Sub total		930,164		922,391
Equity Method Investments, net
BioFirst Corporation		76,369		268,336
Rgene Corporation		-		-
Total	$	1,006,533	$	1,190,727

(a)	BioFirst Corporation (the “BioFirst”):

The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of September 30, 2021 and December 31, 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During the nine months ended September 30, 2021, the Company made prepayment for equity investment in BioFirst to purchase additional 297,000 shares to be issued by BioFirst in the aggregate amount of $639,738, recorded as prepayment for long-term investments as of September 30, 2021.

Summarized financial information for the Company’s equity method investee, BioFirst, is as follows:

Balance Sheet

	September 30, 2021		December 31, 2020
	(Unaudited)
Current Assets	$	1,752,070	$	1,299,822
Non-current Assets		2,533,136		2,540,041
Current Liabilities		2,680,177		1,986,340
Non-current Liabilities		40,008		73,197
Stockholders’ Equity		1,565,021		1,780,326

Statement of Operations

	Nine months Ended September 30,
	2021			2020
	(Unaudited)
Net sales	$	17,451		$	134,759
Gross profit		5,414			6,397
Net loss		(887,230	)		(4,936,294	)
Share of losses from investments accounted for using the equity method		(193,147	)		(1,067,298	)

(b)	Rgene Corporation (the “Rgene”)

Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of September 30, 2021 and December 31, 2020, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.

Summarized financial information for the Company’s equity method investee, Rgene, is as follows:

Balance Sheets

	September 30, 2021			December 31, 2020
	(Unaudited)
Current Assets	$	81,599		$	123,958
Noncurrent Assets		376,369			412,342
Current Liabilities		1,765,628			1,392,756
Noncurrent Liabilities		9,897			38,953
Shareholders’ Deficit		(1,317,557	)		(895,409	)

Statement of Operations

	Nine months Ended September 30,
	2021			2020
	(Unaudited)
Net sales	$	-		$	16,449
Gross Profit		-			(332,763	)
Net loss		(411,897	)		(441,678	)
Share of loss from investments accounted for using the equity method		-			-

(4)	Disposition of long-term investment

During the year ended December 31, 2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the same period. During the nine months ended September 30, 2021, there is no disposition of long-term investment.

(5)	Losses on Equity Investments

The components of losses on equity investments for each period were as follows:

	Nine months Ended September 30,
	2021			2020
	(Unaudited)
Share of equity method investee losses	$	(193,147	)	$	(1,067,298	)